A two-week course of an experimental immunotherapy called teplizumab dramatically reduced type 1 diabetes (T1D) diagnosis rates in people at high risk for the disease, according to newly published phase II clinical trial results. This is the first time a drug has been able to delay or prevent the disease, which affects 2 million people in the United States.

A study has lodged a new kink in the breastfeeding dilemma that adds to the angst of exhausted new parents: While most newborns lose weight in the first days of life, do you or don’t you offer a little formula after breastfeeding if the weight loss is more than usual?